Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ZCAR~~.20 breakout ,,http://charts.stockfetcher.com/sfchart/a1mdWhD0Tp.png
$CBDW Barchart Buy opinion - https://barchart.com/stocks/quotes/CBDW/opinion
$CYCA: Cytta Corp and FIZUAS Team Up to Enhance Drone and Streaming Tech for Law Enforcement: Cytta Corp. (Stock Symbol: CYCA)
June 25, 2024
Click here:
https://www.einpresswire.com/article/722643501/cytta-corp-and-fizuas-team-up-to-enhance-drone-and-streaming-tech-for-law-enforcement-cytta-corp-stock-symbol-cyca
From the article:
Technology Solutions Provider Addressing Various Industries for Integration, Streaming, Transfer and Storage of Video and Audio Data.
Partnered with FIZUAS Unmanned Aircraft Systems to Dominate the American Drone Reseller and Advanced Streaming Technology Market.
Launched Crisis Alert and Response Emergency System Mobile Application to Revolutionize School Safety.
Instant SOS Alert Automatically Triggers a Video Call That is Shared with All Emergency Responders Responsible for Protecting a School.
Initiative for Florida Law Enforcement Agencies Generates Overwhelming Response Amid New Drone Regulation Changes.
Strong Success for Groundbreaking AI-Enhanced Marketing Campaign in Florida.
Multiple Florida Police Departments and Sheriff's Offices Choosing CYCA CyttaCOMMS as their Drone Streaming Solution.
$EWRC Accumulating Here With News on the Way Next Week! Revenues will be Following!
https://x.com/eworld_company
$CCTG News: CCSC Technology International Holdings Limited Enters into International Purchase Agreement with SHI / LIGHTCARE-SOLUTIONS ApS
Hong Kong, June 20, 2024 (GLOBE NEWSWIRE) -- CCSC Technology International Holdings Limited (the “Company” or “CCSC”) (Nasdaq: CCTG), a Hong Kong-based company that engages in the sale, design and manufacturing of interconnect products, including connectors, cables and wire harnesses, today announced that it has entered into an international purchase agreement (the “Agreement”) with SHI / LIGHTCARE-SOLUTIONS ApS (“SHI”), a Danish company that primarily engages in the design and supply of healthcare lighting products.
Pursuant to the Agreement, CCSC will manufacture and supply healthcare lighting products based on the designs provided by SHI to customers in the Asia Pacific region. Under this Agreement, the parties estimate that the annual purchasing amount will start at €0.50 million (approximately US$0.54 million) in 2025 and increase to €3.50 million (approximately US$3.76 million) in 2030.
Mr. Kung Lok Chiu, Chief Executive Officer and Director of the Company, commented, “We are thrilled to partner with SHI to expand our healthcare lighting business in the Asia Pacific market. This partnership aligns with our strategic goal of diversifying our product portfolio and expanding our presence in the healthcare sector. Through our collaboration with SHI, we are poised to deliver innovative and effective lighting solutions that meet the needs of customers in the healthcare industry. We believe this collaboration will drive growth for both companies in the foreseeable future.”
About CCSC Technology International Holdings Limited
CCSC Technology International Holdings Limited, is a Hong Kong-based company that engages in the sale, design and manufacturing of interconnect products. The Company specializes in customized interconnect products, including connectors, cables and wire harnesses that are used for a range of applications in a diversified set of industries, including industrial, automotive, robotics, medical equipment, computer, network and telecommunication, and consumer products. The Company produces both OEM (“original equipment manufacturer”) and ODM (“original design manufacture”) interconnect products for manufacturing companies that produce end products, as well as electronic manufacturing services (“EMS”) companies that procure and assemble products on behalf of such manufacturing companies. The Company has a diversified global customer base located in more than 25 countries throughout Asia, Europe and the Americas. For more information, please visit the Company’s website: http://ir.ccsc-interconnect.com.
Forward-Looking Statements
Certain statements in this announcement are forward-looking statements, including, but not limited to, the Company's proposed Offering. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “may,” “will,” “could,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “propose,” “potential,” “continue”, or other similar expressions in this press release. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the U.S. Securities and Exchange Commission.
For more information, please contact:
CCSC Technology International Holdings Limited
Investor Relations Department
Email: ir@ccsc-interconnect.com
Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com
ESM Confirms Validity of Mining Licence and Option to Extend
https://www.globenewswire.com/news-release/2024/06/21/2902461/0/en/Euro-Sun-Mining-Confirms-Validity-of-Mining-Licence-and-Option-to-Extend.html
OrbitBeyond is excited to announce we have purchased the control block, of public entity $MAYX. Official press to follow.
— OrbitBeyond (@OrbitBeyond) June 16, 2024
Risk Checks For PlantX Life - June 2024
We perform risk checks on every company. We flag any failed checks as potential investment risks. A company which passes all our checks, however, is not 'risk free'.
PlantX Life Inc. (PLTX.D) Risk Checks
Fail
Is their share price liquid and stable?
Highly volatile share price over the past 3 months
Share Price
Fail
Are they in a good financial position?
Has less than 1 year of cash runway
Section 4.4
Fail
Do they have negative shareholders equity?
Have negative shareholders equity
Section 4.2
Fail
Have shareholders been diluted over the past year?
Shareholders have been substantially diluted in the past year
Section 7.3
Fail
Do they have a meaningful market capitalization?
Does not have a meaningful market cap ($1M)
Section 8.0
Source; Simply Wall St June -24
New information has come out, that S Dollinger is not playing a fair game.
His old fraud (see article) never got to the court, yet now might be different.
https://www.greenmarketreport.com/namaste-tec...g-company/
The recent share deal 1/34 is not beneficial for retail investors -
and no explanations has come out on why was it set up in this way?
A clear pressrelease on the fact of the matter, so all can take part and
understand - now it`s smoke and mirrors, why share price will probably
continue to fall, as more retail investors come to see trough this.
ZCAR~~.182,soon $3.00++
ZCAR~~.163, next FFIE, $3.0+++ pps soon
ZCAR~~could see $4.00 dollars
Warning guys to protect your money stay away of pace metal stocks Pace.v
$ACGX News: Alliance Creative Group (ACGX) Releases Q1 2024 Financial and Disclosure Report with an 88% increase in Net Income from Q1 2023 to Q1 2024
CHICAGO, May 15, 2024
West Devon Property listed for sale at $3.950,000 with a 7.97% Cap Rate
CHICAGO, May 15, 2024 /PRNewswire/ -- Alliance Creative Group, Inc., (http://www.ACGX.us) (Stock Symbol OTC: ACGX) is pleased to announce the results of Operations for the Quarter Ending March 31, 2024.
Revenues for the Quarter ending March 31, 2024 ("Q1 2024" were $217,916 Gross Profits for the Quarter ending March 31, 2024 ("Q1 2024" were $217,916 Net Income for the Quarter ending March 31, 2024 ("Q1 2024" were $142,330
The total assets on the Balance Sheet for the Alliance Creative Group as of 3/31/24 were $4,531,689
The total outstanding common shares as of March 31, 2024 were 4,454,211 with 2,799,023 of those shares in the float - Same as the end of the third quarter.
The Company ended the quarter with $156,554 Cash on hand.
The property located at 1324 W. Devon Ave, Chicago, IL. 60660 has been listed for sale at $3,950,000 ($246,975 per Unit) with a 7.97% Cap Rate - Link below:
https://www.loopnet.com/Listing/1324-W-Devon-.../31610262/
The full financial statement, balance sheet, statement of operations, cash flow statement, and disclosure statements are posted on the OTC Market Company website at www.OTCmarkets.com under the stock symbol ACGX in the section for filings and disclosure and on www.ACGX,us in the investor relations section.
Paul Sorkin, CEO of the Alliance Creative Group, Inc. said, "This quarter was a continuation of keeping our expenses as low as possible while we attempt to sell the 1324 W. Devon property and look for the next best strategic investment, acquisition, or partnership to continue to grow our positive cashflow and position ourselves for potentially larger opportunities.
PeopleVine had another strong quarter and we are engaging in multiple conversations to determine the best next steps for us.
Overall we are in search of a potential strategic acquisition or project that can leverage our foundation to grow and scale faster than on their own. We will continue to update the public as things progress and will share more details as they become available."
About Alliance Creative Group, Inc.
Alliance Creative Group, Inc. (Stock Symbol: ACGX) is a Parent Holding Company on the OTC market. The strategy ACG intends to deploy is a shared resource model where internal divisions, portfolio companies, Real Estate projects, and strategic investments are vertically integrated, optimizing efficiencies and cost savings. Resources may be applied to a mix of early-stage equity investments in companies that synergize with the company's shared resource model and secured investment opportunities. ACG's strategic mission is to utilize a unique blend of capital, relationships, experience, and secured investment structures to increase value for its clients, partners, investors, and shareholders while reducing the overall risk. The company's big picture long term plan is to create an ecosystem of shared resources that can provide quality resources with reduced expenses while acting as a partner for internal projects. The intent is to have multiple businesses and investment projects or divisions to help diversify the risk and generate potential revenue in multiple ways while leveraging both the private and public markets. For more information, visit www.AllianceCreativeGroup.com or www.ACGX.us.
About PeopleVine
PeopleVine is a Software as a Service (SAAS) company that specializes in serving the Lifestyle Hospitality industry. The Member Experience & CRM Software allows luxury hotels, resorts, and private member clubs to elevate a more personalized online membership experience. PeopleVine helps their clients build member communities, drive engagement, and connect the dots that elevate experiences and revenues. The software empowers its clients teams to deliver efficiently managed operations through an integrated platform. PeopleVine is committed to being the most essential and adaptive SaaS engagement platform for companies that take a customer centric approach to business.
For more information www.PeopleVine.com
About Say Less Spritz
Say Less Spritz is a low ABV premium light wine in a can. Say Less blends a carefully sourced selection of West Coast rosé and wine varietals with sparkling water and real fruit juice to create a single serving ready to drink (RTD) wine in a can. The Award winning Products come in 6 flavors: Classic Rosé Spritz, Pineapple Rosé Spritz, Watermelon Rosé Spritz, Pinot Noir, Chardonnay, and Sauvignon Blanc. All products are 100 calories or less, 5 grams of sugar or less, and contain all natural ingredients. The rosé collection is sweetened with monk fruit to provide a cleaner and more enjoyable drinking experience without compromising on taste or quality. Currently, Products can be found in over a dozen states and in over 1,000 stores. Some retailers include: HEB, Jewel Osco, Meijer, Liquor Barn, and lots more, as well as GoPuff and SpiritHub online. Product can also be found in iconic venues such as Wrigley Field, The Grand Ol' Opry, and The Philadelphia Zoo, where the brand continues to captivate wine enthusiasts who are looking for a refreshing and convenient beverage choice.
This news release contains forward-looking statements as defined by the bespeaks-caution doctrine. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks described in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by the cautionary statements that may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
For more info: www.SayLessSpritz.com
Investor Relations and Media Contact
1-312-498-9769; info@ACGemail.com
Cision View original content:https://www.prnewswire.com/news-releases/alliance-creative-group-acgx-releases-q1-2024-financial-and-disclosure-report-with-an-88-increase-in-net-income-from-q1-2023-to-q1-2024-302146296.html
SOURCE Alliance Creative Group, Inc.
The CEO Largest Insider Shareholder! South African leading critical mining project , the EU prioritised metals from Euro Sun Mining - is now offficialy on the governments new "Europe's Critical Raw Materials Act" (the CRMA), see post 274. The CEO of the company, has made calculated moves during the time he been leading ESM.
https://www.eurosunmining.com/
(see video on YouTube)
Being the largest INSIDER SHAREHOLDER - Close to 4% of OS - specialised in quick turnaround of projects (see his resumè). Allegedly not taking any salary now until 2026, at the start of first production; latest video interview with Mr. Grant Sboros:
Ya. PPCB looking great here with 3 tall volume soldiers at.0008. They also are currently in the preclinical phase of development for their Cancer drug - PRP. Undervalued!
$AVRW: Avenir Wellness / Sera Labs Inc. Partnership with Nicole Kidman - FabFitFun and Influencer Endorsements Drive Sales Growth for Seratoptical Revolutions Skin : Avenir Wellness Solutions, Inc. (Stock Symbol: AVRW)
https://www.einpresswire.com/article/711238053/solid-growth-for-seratoptical-revolutions-skin-care-line-boost-from-famed-fabfitfun-many-key-celebrities-otc-avrw
In this article:
Proprietary Nutraceutical & Topical Delivery Systems for Wellness and Anti-Aging Beauty Product Lines.
Company Currently Holds 15 Patents.
Seratopical Revolution Skin Care is Personally Used and Endorsed by Global Brand Ambassador & Strategic Partner Nicole Kidman and Other Major Celebrities.
LA-Based Facial Plastic Surgeon Dr. Michael Persky Directly Supporting All Seratopical Revolution Plant-Based Products, Backed by Science with New “Ask the Expert” Videos, Answering Questions Directly from Customers.
Net Revenue in Q4 of 2023 Increased to $1.1 Million or 11.7%, Also Increased Sequentially from Q3 2023 by $43 Thousand, or 4.4%.
Sales Benefits Commencing From New Relationship with Leading Online and Beauty Subscription Box Retailer, FabFitFun.
ISM~~$2.14,load big,$10.00+++ on the corner,,https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174469407
IZM~~2.13,, CHARTS
DAILY AND WEEKLY CHART ,https://stockcharts.com/freecharts/gallery.html?IZM
ADX (14)~ chart,,https://stockcharts.com/h-sc/ui?s=izm&p=D&yr=0&mn=6&dy=0&id=p46634481126
Stochastic ,FAST STO and FULL STO,,https://stockcharts.com/h-sc/ui?s=izm&p=D&b=5&g=0&id=p21973678006
PSAR chart,https://stockcharts.com/h-sc/ui?s=izm&p=D&yr=0&mn=6&dy=0&id=p91663972541
Daily chart, https://stockcharts.com/h-sc/ui?s=izm&p=D&yr=0&mn=3&dy=0&id=p81682029007
MA(50),MA(200) and RSI(14), https://stockcharts.com/h-sc/ui?s=izm&p=D&yr=0&mn=6&dy=0&id=p06455731712
Accum/Dist and MFI(14) chart,https://stockcharts.com/h-sc/ui?s=izm&p=D&yr=0&mn=6&dy=0&id=p31873288935
IZM~~2.02 load up big,2000%% +++++breakout,,https://stockcharts.com/freecharts/gallery.html?IZM
$CBDW is pleased to provide an update on our recent sales push for IR Chat and the latest Company filings. https://finance.yahoo.com/news/1606-corp-reports-great-success-120000601.html
Ooops... 46% UP!! I stand corrected, see my previous post.
Now, let`s see today. PlantX Life wakes up to a new spring!
Good luck all good people out there
https://www.facebook.com/groups/281295698392004
(say hi smile
https://vegainvestors.com/
BULLISH
$CBDW 1606 Corp. Reports Great Success on IR Chat Sales Push and Shows Increased Revenue Last Quarter. https://www.reddit.com/r/10xPennyStocks/comments/1cxelvg/1606_corp_reports_great_success_on_ir_chat_sales/?utm_source=share&utm_medium=web3x&utm_name=web3xcss&utm_term=1&utm_content=share_button
$CBDW 1606 Corp. Reports Great Success on IR Chat Sales Push and Shows Increased Revenue Last Quarter.
SISI~$1.15 load up,will be insane
$GNPX: Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
Expects to Initiate the Phase 2 Expansion Study in the Second Half of 2024
Acclaim-3 Study Supported by FDA Orphan Drug and Fast Track Designations
AUSTIN, Texas, May 14, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the first patient has been enrolled and dosed in the Company's Phase 1 dose escalation portion of the Acclaim-3 clinical study of Reqorsa® (quaratusugene ozeplasmid) Immunogene Therapy in combination with Genentech's Tecentriq® to treat patients with extensive-stage small cell lung cancer (ES-SCLC).
"We are excited to take this next step in our fight against lung cancers as we work to advance an innovative therapy that we believe provides hope to patients suffering with ES-SCLC, an especially aggressive form of lung cancer that has extremely limited treatment options," said Ryan Confer, President and Chief Executive Officer at Genprex. "With a median progression free survival (PFS) of 5.2 months, ES-SCLC has a particularly poor prognosis. Additionally, patients receiving Tecentriq as maintenance therapy have a median PFS of 2.6 months after the start of maintenance therapy. With such limited benefit from current treatments, we believe the combination of REQORSA and Tecentriq can provide a promising new therapeutic option for the treatment of small cell lung cancer."
"The Phase 1 dose escalation portion of the Acclaim-3 study is expected to determine the maximum tolerated dose for the Phase 2 expansion study," stated Mark Berger, M.D., Chief Medical Officer of Genprex. "The favorable results from our Phase 1 Acclaim-1 study in non-small cell lung cancer (NSCLC) enabled us to shorten the Phase 1 portion of Acclaim-3. This should allow us to complete the Phase 1 portion of the study during the second half of 2024 and to advance more quickly into the Phase 2 expansion portion of Acclaim-3 in the second half of 2024. We look forward to providing study updates as we advance this potentially life-saving therapy to benefit patients battling ES-SCLC."
Genprex has a novel cancer treatment platform that re-expresses tumor suppressor genes in cancers. Tumor suppressor genes are often deleted or inactivated early in the process of cancer development. REQORSA contains a plasmid that expresses TUSC2, a tumor suppressor gene protein. Nearly 100% of SCLCs have reduced or no TUSC2 protein expression, and 41% completely lack TUSC2 protein expression. Nonclinical studies in mice support the hypothesis that re-expressing the TUSC2 protein may lead to improved clinical efficacy in combination with Tecentriq.
About the Acclaim-3 Clinical Trial
The Acclaim-3 clinical trial is a Phase 1/2 open-label, dose escalation and clinical response study of maintenance therapy evaluating REQORSA in combination with Tecentriq in patients with ES-SCLC. The Acclaim-3 clinical trial will enroll patients who did not develop tumor progression after receiving Tecentriq and chemotherapy as standard initial treatment, and who are therefore eligible for maintenance therapy.
The Phase 1 dose escalation portion of the Acclaim-3 clinical study is expected to enroll up to 12 patients at approximately ten U.S. clinical sites to determine the Maximum Tolerated Dose (MTD). If no dose limiting toxicities occur during the Phase 1 study, the highest dose evaluated will be the Recommended Phase 2 Dose. The Phase 2 portion of the study is expected to enroll approximately 50 patients at ten to fifteen U.S. sites. Patients will be treated with REQORSA and Tecentriq until disease progression or unacceptable toxicity is experienced. Genprex expects to initiate the Phase 2 expansion study in the second half of 2024.
The primary endpoint of the Phase 2 portion of the trial is to determine the 18-week progression-free survival rate from the time of the start of maintenance therapy with REQORSA and Tecentriq treatment in patients with ES-SCLC. Patients will also be followed for survival. A Phase 2 futility analysis will be performed after the 25th patient enrolled and treated reaches 18 weeks of follow up.
Genprex has received U.S. Food and Drug Administration (FDA) Ophran Drug and Fast Track designations for Reqorsa® Immunogene Therapy, in combination with Genentech, Inc's Tecentriq® in patients with ES-SCLC who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. Additional information about the Acclaim-3 clinical trial can be found by visiting ClinicalTrials.gov.
About Reqorsa® Immunogene Therapy
Reqorsa® (quaratusugene ozeplasmid) Immunogene Therapy for NSCLC and SCLC consists of the TUSC2 gene expressing plasmid encapsulated in non-viral nanoparticles made from lipid-based molecules in a lipoplex form (Genprex's Oncoprex® Delivery System) with a positive electrical charge. REQORSA is injected intravenously and specifically targets cancer cells, which generally have a negative electrical charge. REQORSA is designed to deliver the functioning TUSC2 gene to cancer cells while minimizing their uptake by normal tissue. REQORSA has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for programmed cell death, or apoptosis, in cancer cells, and modulates the immune response against cancer cells. In addition, REQORSA disrupts the metabolism of cancer cells by decreasing glycolysis and ATP production in cancer cells with decreased TUSC2.
Genprex's strategy is to develop REQORSA in combination with currently approved therapies and believes that REQORSA's unique attributes position it to provide treatments that improve on current therapies for patients with NSCLC, SCLC, and possibly other cancers.
Tecentriq® is a registered trademark of Genentech, Inc.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa® (quaratusugene ozeplasmid) Immunogene Therapy, is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's three lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn.
Cautionary Language Concerning Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2023.
Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials and regulatory approvals; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex's intellectual property and licenses.
These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.
Genprex, Inc.
(877) 774-GNPX (4679)
GNPX Investor Relations
investors@genprex.com
GNPX Media Contact
Kalyn Dabbs
media@genprex.com
ALCOHOL - and how to profit from it in a "new way", check the video;
$BSEM Reports Big Jump in Revenue and Margin
Revenue: Increased to $41.9 million in Q1 2024 from $600,000 in Q1 2023.
Gross Margin: Rose to 95% in Q1 2024 from 82% in Q1 2023.
Net Income: Reported positive for the first time on a US GAAP basis.
Operating Expenses: Grew to $35.1 million in Q1 2024, up from $3.1 million in Q1 2023.
Gross Profit: Increased to $39.7 million or 95% of revenue in Q1 2024 from $500,000 or 18% of revenue in Q1 2023.
https://finance.yahoo.com/news/biostem-technologies-inc-bsem-q1-070914107.html
$BLIS News: Company Name Change to NAPC Defense, Inc. (OTCPK: BLIS) and Website to NAPCDefense.com among Business Updates
NAPC Defense has also set visit to Saudi Arabia for presentation of The Corner Shot Weapons System and other NAPC New Arms Technologies
LARGO, Fla., May 13, 2024 (GLOBE NEWSWIRE) -- NAPC Defense, Inc. (formerly known as Treasure & Shipwreck Recovery, Inc.), trading as (OTCPK: BLIS), announces that it has completed the change of name with the State of Nevada and registration with the State of Florida, as well as a new website at http://www.NAPCDefense.com. It is also finalizing its application with FINRA to effect all additional merger terms announced in the March 27, 2024 press release. NAPC Defense, Inc. owns defense and construction contracting firm Native American Price Constructors, LLC.
More importantly, NAPC is pleased to update its intended large purchase order from a Saudi Arabian company. Field demonstrations for The Corner Shot Weapons Systems will occur in the Kingdom of Saudi Arabia before government, military and other officials during a visit set for the first two weeks of July 2024.
While NAPC maintains a government contracting business, its business includes The Corner Shot Weapons Systems, which is licensed for the United States and the Middle East, as well as brokering of large caliber artillery, mortar, rocket, and smaller caliber munitions sales through allied countries, as approved by the U.S. State Department.
The Saudi Arabia meetings will be for assessment and introduction of the continued contract goal of providing the Corner Shot technology to Saudi Arabia, under a U.S. approved and licensed export of the tactical arms technology. NAPC is a joint venture partner in Saudi Arabia, in the joint venture of NAPC-KSA which is co-owned by NAPC, Kingswood Holding LLC., and AL-SAQR AL–HARR Limited Company. NAPC already has a signed and stamped LOI from a leading Saudi Arabian provider of supply and manufacturing to the Ministry of Defense (MOD).
NAPC management is also in discussion with the Kingdom of Saudi Arabia to provide additional services such as Military Fuzing, and Artillery systems in country, pending expected U.S. State Department approval. NAPC expects significant discussions to expand during the official visit in this arena.
In expanding its arms related business, NAPC is also developing a rifle and suppressor line for domestic government and international sales. NAPC expects to release more information on these product lines in the short term as prototypes are being completed for testing.
NAPC will also be participating in a number of law enforcement conventions to display The Corner Shot and other product lines. Such conventions and shows include Florida Police Chiefs Assoc. 72nd Annual Summer Training Conference & Exposition in Pointe Vedra Beach, FL – June 7th – 12th 2024 (Booth #139) and 38th Annual NJ Police Security Expo. in Atlantic City, NJ – June 24th – 26th (Booth #1037).
Finally, NAPC Defense is active in brokering of munitions and military hardware already produced and in inventory at various locations worldwide. NAPC is currently brokering a number of different munitions and military hardware items that are of interest to Allied and NATO forces for the Ukraine and the Middle East, which also require U.S. State Department approval. Any successful transaction would add significantly to NAPC revenues and profits. The inventory of these items, if sold at currently offered fair value, totals over (U.S.) $2.5 billion.
NAPC will update the status of its corporate actions, weapons development, and shows in future releases.
About NAPC Defense, Inc.
NAPC Defense, Inc. (https://www.napcdefense.com/) is an armament sales and production company, fully licensed in the United States, with exclusive rights to produce and sell Corner Shot USA weapons systems, in addition to brokering arms and munitions throughout the world all with US State Department approval. Additional smaller weapons platforms and related products are in development.
Please go to https://www.napcdefense.com/investor-relations for Investor Relation Page.
FORWARD LOOKING STATEMENTS:
This press release and the statements of representatives of NAPC. (the "Company") related thereto contain, or may contain, among other things, "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact included herein are "forward-looking statements," including any other statements of non-historical information. These forward-looking statements are subject to significant known and unknown risks and uncertainties and are often identified by the use of forward-looking terminology such as "guidance," "projects," "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "ultimately" or similar expressions. All forward-looking statements involve material assumptions, risks and uncertainties, and the expectations contained in such statements may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results (including, without limitation, NAPC's ability to advance its business, generate revenue and profit and operate as a public company) could differ materially from those stated or anticipated in these forward-looking statements as a result of a variety of factors, including factors and risks discussed in the periodic reports that the Company files with the SEC. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. The Company undertakes no duty to update these forward-looking statements except as required by law.
COMPANY CONTACT:
Kenny West, CEO
kwest@napconstructors.com
754-242-6272
NCO~$1.20 ~WEBSITE~~ https://www.neo-ig.com/service
Book Value on $LYRA: $1.48. Trading at .36 ....Trading at 25% Book Value...damn.......lol.......
Z
VHAI~~MA5 @.147,, MA10 @.161,,MA 20@ .206 ,,,https://stockcharts.com/h-sc/ui?s=vhai&p=D&b=5&g=0&id=p21973678006
VHAI~~.194 hits AH, mega breakout going next week
VHAI~~.18,load fellas AI company gonna see dollars again
$RENB News: RenovaroCube to Acquire 100% Ownership of Cyclomics, Reinforcing Cutting-Edge Cancer Diagnostics Partnership
LOS ANGELES and AMSTERDAM, April 24, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (Nasdaq: RENB), a trailblazer in AI-driven early cancer diagnostics and therapeutics, and Cyclomics, a leader in ultra-sensitive 4th generation multi-omics molecular biology, proudly announce a significant milestone in their collaboration. RenovaroCube has entered into an amendment to its binding letter of intent to acquire 100% ownership of Cyclomics, further cementing their shared commitment to advancing state-of-the-art technologies in cancer diagnostics and treatment. Their combined relationships with Oxford Nanopore and Nvidia will further position RenovaroCube to be a leader in early cancer diagnostics and monitoring of treatment efficacy. Oxford Nanopore is a leader in sequencing technologies and Nvidia will provide vital super computing power and front edge software solutions such as Parabricks, BioNeMo, Monai and Nemo.
Initially set at a 75% acquisition, this decision to acquire the remaining 25% of Cyclomics reflects the resounding success of their partnership and the remarkable synergy between the two companies. Upon closing, we believe the acquisition of Cyclomics into the Renovaro family will further strengthen our ability to create a powerhouse for cancer diagnostics throughout the entire patient journey, from early detection/recurrence and personalized treatment in late-stage disease. "We believe that this combination can transform the landscape of patient care both for early detection as well as for monitoring continuously the therapeutics given,” according to Dr. Coenraad K. van Kalken (MD/PHD), Chief Commercial Officer of RenovaroCube.
RenovaroCube's open architecture Artificial Intelligence platform, known as the Cube, currently houses over 3600 high-performance biomarker panels for 13 different cancers. This molecular differential AI platform utilizes multi-omic analysis combined with proprietary algorithms and when coupled with Cyclomics' groundbreaking 4th generation molecular technology, shall be able to decode multi-omic data from just a single vial of blood. "We will work with Cyclomics from ‘strength to strength’ providing combined technologies, expertise, and resources which will make us unique and offers what we believe will be an unprecedented accuracy in non-invasive early cancer detection,” added Dr. Henk Viëtor (MD/PHD).
Cyclomics has pioneered a groundbreaking diagnostic method named ‘CyclomicsSeq’ for monitoring early cancer recurrence, utilizing Oxford Nanopore sequencing technology they have created an assay in partnership with Oxford Nanopore that provides detection of even a single ctDNA molecule in blood with nearly 100% accuracy. Additionally, Cyclomics' OmniOmics 4th generation technology enables reliable, fast, and ultra-sensitive early detection of cancer or recurrence thereof using next-generation whole genome sequencing.
"We are excited to join forces with Renovaro to drive the next wave of innovation in molecular biology integrated into an advanced proprietary AI/ML platform," commented Alessio Marcozzi, CSO of Cyclomics. "This combination reflects our shared commitment to pushing the boundaries of what is possible in our respective fields."
About Renovaro:
Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro includes Renovaro Bio with its advanced cell-gene immunotherapy company and RenovaroCube. RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective. RenovaroCube is a molecular data science company with a background in FinTech and a 10-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.
Upon the closing of the acquisition of Cyclomics (winner of the Health Holland Venture Challenge), RenovaroCube will be capable of performing liquid biopsies using proprietary technologies to identify single cancer DNA molecules in only one vial of blood. In combination with Oxford Nanopore Technology, genetic information can be retrieved over multiple genetic layers to develop the next generation of cancer diagnostics. This has the potential to transform cancer care by enabling faster and more accurate diagnosis throughout the patient journey.
The combined Companies aim to Disrupt Cancer Diagnosis and treatment through early disease and recurrence detection, prediction of response to treatment, and personalized therapy.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline and platform. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For media inquiries, please contact: karen@renovarocube.com
Source: Renovaro Inc.
ARLSF~~.1512 load fellas, chart will break insane, low floaters goes crazy when volume pouring
$RENB News: Renovaro Inc. Proudly Announces the Appointment Of Professor Dr. Geert Kazemier as the Chairman of its Scientific Advisory Board, A Move That Heralds a New Era of Innovation and Progress in its Mission to Reshape Cancer Screening, Diagnosis, and Patient Care
LOS ANGELES and AMSTERDAM, April 18, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (Nasdaq: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, announces the distinguished Professor Geert Kazemier, MD, PhD, as the new Chairman of its Scientific Advisory Board. This pivotal move signifies a major leap forward in Renovaro’s quest to redefine cancer diagnosis and treatment through cutting-edge AI and immunotherapy technologies.
Professor Kazemier is the Clinical Director and scientific co-director of the Cancer Center at Amsterdam University Medical Center. The center has an extensive repository of biobank tumor material and liquid biopsies, including an extensive range of data from biomarkers, amongst others, for co-rectal, urogenital, lung, and breast cancers.
Professor Kazemier has made groundbreaking contributions to oncology and surgical research. His depth of experience and trailblazing academic and clinical leadership align perfectly with Renovaro's mission. Professor Kazemier's commitment to medical advancement positions him as an ideal leader to propel Renovaro's Scientific Advisory Board during a transformative era in oncology characterized by the integration of Artificial Intelligence.
Under Professor Kazemier’s direction, Amsterdam University Medical Center’s Cancer Center has launched numerous pioneering research projects, substantially enriching our understanding and treatment of cancer. His drive for innovation and excellence echoes Renovaro’s dedication to advancing early diagnosis, accurate response prediction, effective monitoring, and personalized therapy.
As the Chairman of the Scientific Advisory Board, Professor Kazemier is set to influence Renovaro's research and development trajectory. We believe his expertise and forward-thinking approach will guide Renovaro in refining the company's strategic initiatives, including data acquisition and biomarker selection, to position Renovaro at the forefront of innovation. His leadership will prioritize novel research paths with the power to potentially transform cancer diagnosis, monitoring, and treatment processes.
“We are honored to have Professor Kazemier join our team,” remarked Hon Mark Dybul, MD, CEO of Renovaro. “His extraordinary achievements in medical research and visionary leadership are tremendous assets to Renovaro. With Professor Kazemier guiding our Scientific Advisory Board, we are even more confident in our global mission to revolutionize patient care through regenerative medicine.”
Expressing his excitement, Professor Kazemier shared, “I am enthusiastic about playing a role in the evolution of Renovaro's AI platform, 'the Cube,' having witnessed its growth from inception to its current state. I am excited to further contribute to Renovaro’s groundbreaking efforts to reshape the landscape of cancer care. I believe the Cube’s potential to shift cancer patient care from diagnosis to therapy is extraordinary. I eagerly anticipate collaborating with Renovaro’s gifted team to steer the company's research towards transformative medical innovations.”
With Professor Kazemier's appointment, Renovaro cements its status as an AI/biotech frontrunner, ready to drive significant advancements in medical science and enhance patient outcomes in the fight against cancer.
About Renovaro:
Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro includes Renovaro Biosciences with its advanced cell-gene immunotherapy company and Renovaro Cube. Renovaro Cube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. Renovaro Cube intervenes at a stage where potential therapy can be most effective. Renovaro Cube is a molecular data science company with a background in FinTech and a 10-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.
Upon the closing of the previously announced acquisition of Cyclomics (winner of the Health Holland Venture Challenge), Renovaro Cube will be capable of performing liquid biopsies using proprietary technologies to identify single cancer DNA molecules in only one vial of blood. In combination with Oxford Nanopore Technology, genetic information can be retrieved over multiple genetic layers to develop the next generation of cancer diagnostics. This will transform cancer care by enabling faster and more accurate diagnosis throughout the patient journey.
About Prof. Kazemier
Professor Geert Kazemier, MD, PhD, went to medical school and trained as an oncologic and transplant surgeon at Erasmus University Rotterdam, The Netherlands. After a fellowship in hepatobiliary surgery and transplantation at Universitätsklinikum-Eppendorf in Hamburg, Germany, he became a Consultant Hepatobiliary Surgery and Transplantation at Erasmus Medical Center and was later appointed Program Leader of Liver Transplantation there. In 2012, he was appointed as a full hepatobiliary surgery and transplantation professor at Amsterdam University Medical Center. He is currently the Clinical Director and Scientific co-director of Cancer Center Amsterdam at Amsterdam UMC. In his research, he aims to put fundamental research to work in clinical practice as he focuses on developing biomarkers for pancreatic and bile duct cancer and investigating the added value of Artificial Intelligence in liver tumors.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline and platform. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For media inquiries, please contact: karen@renovarocube.com
Source: Renovaro Inc.
$AVRW is starting to climb now. High prospects to deliver a record sales growth year in 2024 with the company's Seratopical brand skin care products used and endorsed by Nicole Kidman. Lots of details in the latest official company news below.
Avenir Wellness Solutions Issues 2024 Marketing Growth Plans to Shareholders for Seratopical Revolution Skin Care Line with Support from Nicole Kidman and Facial Plastic Surgeon Dr. Michael Persky
New TikTok Shop Ready for Launch to Help Grow Brand Awareness and Product Sales
News Link:
https://finance.yahoo.com/news/avenir-wellness-solutions-issues-2024-140000098.html
New Video CEO Sean Dollinger Spills Secrets in Interview with Michael Nauss!
Analysts target price range for PlantX Life Inc. The bear-bull range indicates that the price target lies between CA$0.89 and CA$4.821
The stock trades also on the OTC.
The board; https://investorshub.advfn.com/PlantX-Life-Inc-VEGA-38643
Exciting news from iQSTEL - $IQST! They just hit record-breaking revenue of $50M+ in Q1 FY-2024, even before counting their latest acquisition. With plans for explosive growth and a focus on essential services like telecom, fintech, EVs, and the metaverse, this stock is on fire! Keep it on your radar!
https://www.prnewswire.com/news-releases/iqst--iqstel-q1-record-breaking-revenue-exceeds-50m-not-including-recent-acquisition-302114251.html
HOLO~~$3.12,is a FREAKING breakout in little, my $50++PPS soon,,https://stockcharts.com/h-sc/ui?s=holo&p=D&yr=0&mn=6&dy=0&id=p06455731712
$IWAL up another 47% today - low float monster!
HOLO~$3.18,,,~CRAZYYYY HUGE BREAKOUT to $50.00++++dollars
https://stockcharts.com/h-sc/ui?s=holo&p=D&yr=0&mn=6&dy=0&id=p06455731712
HOLO~~CRAZYYYY HUGE BREAKOUT to $50.00++++dollars
https://stockcharts.com/h-sc/ui?s=holo&p=D&yr=0&mn=6&dy=0&id=p06455731712
Followers
|
402
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
12198
|
Created
|
12/21/10
|
Type
|
Free
|
Moderator ALERTS100%to10000%GAIN | |||
Assistants mick stockyupydowny |
https://www.youtube.com/watch?v=baJPnJMN5eE
city of hickory water bill - Search (bing.com)
https://www.2024dieselsettlement.com/Content/Documents/Claim%20Form.pdf
https://www.biospace.com/news/
https://finviz.com/
http://www.lowfloat.com/all_with_otcbb/2
https://www.prnewswire.com/news-releases/
http://thestockmarketwatch.com/markets/pre-market/today.aspx
https://finviz.com/news.ashx
Press Release Distribution and Management (globenewswire.com)
https://www.secinfo.com/
https://www.walmart.com/ip/SheaMoisture-After-Shave-Elixir-Tea-Tree-Oil-Shea-Butter-4-oz/198441014?action=SignIn&rm=true
https://www.walmart.com/ip/SheaMoisture-After-Shave-Elixir-Tea-Tree-Oil-Shea-Butter-4-oz/198441014?action=SignIn&rm=true
https://ih.advfn.com/markets/nasdaq/premarket
https://ih.advfn.com/markets/nasdaq/premarket
https://www.amazon.com/Naked-Truth-about-Sex-Marriage/dp/1549904876/ref=sr_1_1?s=books&ie=UTF8&qid=1519934288&sr=1-1&keywords=naked+truth+sex&_encoding=UTF8&tag=marriagetoday-20&linkCode=ur2&linkId=22a766a990f4774fbc3e7d696a42a94d&camp=1789&creative=9325
https://christiananswers.net/q-eden/sex-oral.html
https://www.copart.com/doRegistration?refId=056911bc-b4f3-45e6-ada2-0fbc6a3944c6-31363157
Homacer Paneled Wood Unfinished Barn Door with Installation Hardware Kit & Reviews | Wayfair
https://www.youtube.com/watch?v=EmSMTJDVuCM
https://www.youtube.com/watch?v=EmSMTJDVuCM
https://www.youtube.com/watch?v=YcSVVhwcNKQ
https://www.youtube.com/watch?v=YcSVVhwcNKQ
https://www.youtube.com/watch?v=EhXz4rFByhM
https://www.youtube.com/watch?v=EhXz4rFByhM
https://www.youtube.com/watch?v=Jap6xYyfBiI
https://www.youtube.com/watch?v=Jap6xYyfBiI
https://www.contractorsdirect.com/Imer-Combicut-250-1000-Wet-Saw#
https://www.contractorsdirect.com/Imer-Combicut-250-1000-Wet-Saw#
https://bible.knowing-jesus.com/Acts/2
https://bible.knowing-jesus.com/Acts/2
https://www.christiantruthcenter.com/how-to-discern-spirits/
https://www.christiantruthcenter.com/how-to-discern-spirits/
https://www.nyse.com/trade-halt-current
https://www.youtube.com/watch?v=MfbXkRCaSbg
https://themarriagebed.com/biology/
https://www.nyse.com/trade-halt-current
https://www.tomorrowsworld.org/magazines/2010/may-june/baptism-ritual-or-requirement
https://www.tomorrowsworld.org/magazines/2010/may-june/baptism-ritual-or-requirement
https://www.32trades.com/market-makers-knowing-what-youre-up-against/
https://www.atlantatrial.com/third-party-debt-collection-lawsuit/
https://www.youtube.com/watch?v=9lAT3y1X7Cg
https://www.bmwpartsnow.com/?msclkid=6fa38b35107f1782c585e98e5acc4ac3&utm_source=bing&utm_medium=cpc&utm_campaign=Search%20%7C%20BMW%20%7C%20Manual&utm_term=BMW%20Replacement%20Accessories&utm_content=Accessories
https://www.otcdynamics.com/kscp-florida-school-deploys-knightscope-autonomous-security-robot-asr/
https://investorshub.advfn.com/boards/profile.aspx?user=372536&page=2
https://www.houseplans.net/floorplans/09800311/modern-farmhouse-plan-2514-square-feet-4-bedrooms-3.5-bathrooms
https://investorshub.advfn.com/boards/profile.aspx?user=372536&page=2
https://www.youtube.com/watch?v=wyADGtlbjdo
https://www.youtube.com/watch?v=wyADGtlbjdo
https://www.youtube.com/watch?v=2k0IkYdgbBE
WELCOME TO THE HOTTEST PENNY STOCK PICKS
WHERE YOU WILL FIND THE POWER OF THE UPSIDE RUNNING !!!!!!!!!
https://www.youtube.com/watch?v=H58SR8ZdilQ
https://www.youtube.com/watch?v=D1kSBlwaWyY ; ,,, the truth about baptism
https://www.youtube.com/watch?v=-a_WqkoQxVM
https://www.youtube.com/watch?v=N_3OgUYE7eQ
https://www.youtube.com/watch?v=pAmGifIj05w
https://www.youtube.com/watch?v=nDZxI3hCpr0
https://www.youtube.com/watch?v=PQ8wSvy26xQ
https://www.youtube.com/watch?v=Ip7AFCNCk6E
https://www.youtube.com/watch?v=xXZ22oVNk2I
https://www.youtube.com/watch?v=Ip7AFCNCk6E
https://www.investorsobserver.com/symbols/nich
https://www.zillow.com/homedetails/1769-31st-Avenue-Ln-NE-65-Hickory-NC-28601/2067604453_zpid/
https://www.investorsobserver.com/crypto/8000/ldo?xifUWGq8AL9M=reload
https://www.investorsobserver.com/crypto/11181/sbr
https://www.investorsobserver.com/crypto/1732/nmr
https://www.investorsobserver.com/crypto/7535/kp3r
https://www.investorsobserver.com/crypto/5824/slp
https://www.investorsobserver.com/crypto/5338/cube
https://www.investorsobserver.com/crypto/9436/elon
https://www.investorsobserver.com/crypto/6843/rad
https://www.investorsobserver.com/crypto/8613/alcx
https://www.investorsobserver.com/crypto/13523/mc
https://www.investorsobserver.com/crypto/1772/storj
https://www.investorsobserver.com/crypto/8075/rly
https://www.investorsobserver.com/crypto/11202/toke
https://www.investorsobserver.com/crypto/6783/axs
https://www.investorsobserver.com/crypto/3155/qnt
https://www.investorsobserver.com/crypto/11289/spell
https://www.investorsobserver.com/crypto/5617/uma
https://www.investorsobserver.com/crypto/5690/rndr
https://www.investorsobserver.com/crypto/7737/api3
https://www.investorsobserver.com/crypto/2586/snx
https://www.investorsobserver.com/crypto/5692/comp
https://www.investorsobserver.com/crypto/6758/sushi
https://www.investorsobserver.com/crypto/7278/aave
https://www.investorsobserver.com/crypto/13855/ens
https://www.investorsobserver.com/crypto/3640/lpt
https://www.investorsobserver.com/crypto/10898/wcfg
https://www.investorsobserver.com/crypto/11566/ash
https://www.investorsobserver.com/crypto/7440/bond
https://coinclarity.com/coin/jasmy/
https://www.wayfair.com/VIGO--Elan-48-52-W-x-74-H-Single-Sliding-Frameless-Shower-Door-with-RollerDisk-Technology-VG6041-L6128-K~VGU2777.html?refid=PINSHOP-vgu2777_49241515&costid=PINSHOP&pin_campaign=626740698783&pin_adgroup=2680063876383&pin_productgroup=4260607568549&device=desktop
https://www.wayfair.com/home-improvement/pdp/dreamline-linea-34-w-x-72-h-frameless-fixed-glass-panel-dln5404.html?piid=29345455
https://www.wayfair.com/home-improvement/pdp/wyndham-collection-beckett-84-double-bathroom-vanity-set-wdx12053.html#ymij4wmjg1-1
https://www.wayfair.com/home-improvement/pdp/upgauge-complete-shower-system-with-rough-in-valve-ugau1004.html
https://www.wayfair.com/home-improvement/pdp/wyndham-collection-beckett-84-double-bathroom-vanity-set-wdx12053.html#ll7n00gluu-5
https://www.wayfair.com/home-improvement/pdp/dreamline-linea-34-w-x-72-h-frameless-fixed-glass-panel-dln5404.html?piid=29345455
https://www.wayfair.com/keyword.php?keyword=shower+folding+sit
https://www.hursthardwoods.com/3-x-3-4-brazilian-cherry-clear-grade-unfinished-solid/3clrjat/
https://somniumtimes.com/2021/10/22/somnium-worlds-are-live/
https://www.youtube.com/watch?v=yjT7bSdwUMg
https://www.geappliances.com/appliance/GE-Profile-30-Built-In-Combination-Convection-Microwave-Convection-Wall-Oven-PT7800SHSS
https://www.geappliances.com/appliance/GE-Profile-30-Built-In-Double-Microwave-Convection-Oven-JT965SFSS
https://www.dlpartsco.com/lookup/178574/1287532
https://www.amazon.sg/GE-WB36T10734-Control-Sub-Asm/dp/B004Q3X1MG
https://www.youtube.com/watch?v=K6Tz9CX4VWE
https://coinclarity.com/coin/shiba-inu/
https://www.reddit.com/r/SHIBArmy/
https://coinmarketcap.com/currencies/shiba-inu/
https://www.youtube.com/watch?v=rFp_EknvKFA
https://www.youtube.com/watch?v=PPijFqEDC8Y
https://www.youtube.com/watch?v=iZc8_9BmRJ0
https://www.youtube.com/watch?v=U_HOLJ3aHtA
https://www.youtube.com/watch?v=BUcT5LHmA7w
https://stockcharts.com/h-sc/ui?s=ptlf&p=D&yr=0&mn=6&dy=0&id=p31873288935
DAYLY AND WEEKLY https://stockcharts.com/freecharts/gallery.html?ptlf
NKWEF https://www.investsmart.com.au/shares/asx-nkp/nkwe-platinum-limited/announcements
http://www.smh.com.au/business/markets/quotes/announcements/NKP/nkwe-platinum-limited
https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001742576&owner=include&count=40
http://m.asx.com.au/m/company-info.xhtml?issuerCode=NKP
http://otce.finra.org/DLSymbolNameChanges ;
https://www.sec.gov/cgi-bin/browse-edgar?action=getcurrent
https://www.sec.gov/edgar/searchedgar/currentevents.htm
https://www.otcmarkets.com/market-activity/news
http://www.secinfo.com/
http://www.lowfloat.com/all_with_otcbb/2
https://www.stockscores.com/index.asp
BCII~~ Analysis http://www.stockta.com/cgi-bin/analysis.pl?symb=BCII&cobrand=&mode=
https://wallmine.com/screener?argp3y=0to100&d=d&o=e&qrg=20to100&r=mo&se=3
https://wallmine.com/otc/mcbp/ipo-year
https://www.spokeo.com/?g=name_gs_C000213&campaignid=54569191&adgroupid=1869444511&creative=89799009271&targetid=kwd-18836056591&placement=&gclid=Cj0KCQjwx43ZBRCeARIsANzpzb--EadF3uP_KiPlEAFkhCjpxd19DxacojZZgFhe1PburzSMqhsde_caAv6VEALw_wcB
https://stockfetcher.com/
BCII daily and weekly http://stockcharts.com/freecharts/gallery.html?BCII
BCII~~Accum/Dist and MFI(14) chart http://stockcharts.com/h-sc/ui?s=bcii&p=D&yr=0&mn=6&dy=0&id=p31873288935
BCII~~MA(50),MA(200) and RSI(14) huge BREAK coming http://stockcharts.com/h-sc/ui?s=bcii&p=D&yr=0&mn=6&dy=0&id=p06455731712
BCII~~daily chart http://stockcharts.com/h-sc/ui?s=bcii&p=D&yr=0&mn=3&dy=0&id=p81682029007
BCII~~SAR http://stockcharts.com/h-sc/ui?s=bcii&p=D&yr=0&mn=6&dy=0&id=p91663972541
BCII~~fast sto and full sto http://stockcharts.com/h-sc/ui?s=bcii&p=D&b=5&g=0&id=p21973678006
BCII~~ADX http://stockcharts.com/h-sc/ui?s=bcii&p=D&yr=0&mn=6&dy=0&id=p46634481126
https://www.benzinga.com/news
1512g Filings - http://1512g.com/
American Stock Exchange - http://www.nyse.com/attachment/amex_landing.htm
Authorized Shares for Nevada and Other States - http://www.authorized-shares.com/
Barrons - http://online.barrons.com/public/main
BioHealth - http://www.biohealthinvestor.com/
BioMed - http://biomedreports.com/
BioSpace - http://www.biospace.com/
Bloomberg - http://www.bloomberg.com
Business News - http://www.bloomberg.com
Business News - http://www.reuters.com/finance/markets
Business News Portal - http://www.businesswire.com/portal/site/home/
BusinessWeek - http://www.businessweek.com/
Candlesticks - www.candlesticker.com/Default.asp
Chart Analysis - www.stockcharts.com/school/doku.php
Chart Video Lessons - http://investorshub.advfn.com/boards/read_msg.aspx?message_id=46647251
Charts - http://bigcharts.marketwatch.com/avatar.asp
Charts - http://chartpatterns.com/
Charts - http://stockcharts.com/
Charts - http://www.incrediblecharts.com/technical/candlesticks.htm
China Business News - http://www.chinadaily.com.cn/bizchina/index.html
China Business News - http://www.xinhuanet.com/english2010/business/index.htm
China Technology News - http://www.chinatechnews.com/
Clinical Trials - http://www.clinicaltrials.gov/
CNBC - http://www.cnbc.com
CNNMoney.com - http://www.money.cnn.com/
Corporate Bankruptcy - http://www.sec.gov/investor/pubs/bankrupt.htm
Corporate Records Search - http://www.coordinatedlegal.com/SecretaryOfState.html
Corporate Records Search - http://www.searchsystems.net/list.php?nid=398
CUSIP number - http://activequote.fidelity.com/mmnet/SymLookup.phtml
DD Amanda - http://ddamanda.com/Members/AmandaChartStart.php
DD Machine - http://www.ddmachine.com/
Deregistering - http://www.aaii.com/commentary/articles/200601_stockstrategies.cfm
Dividends - http://www.dividenddetective.com/
Document Research - http://www.10kwizard.com/main.php
Earnings - http://www.earningswhispers.com/calendar.asp
Education - http://www.investopedia.com/?viewed=1
Email Address Verifier - http://verify-email.org/
EYE ON THE FDA - http://www.eyeonfda.com/
FINRA Daily Short List - www.regsho.finra.org/regsho-Index.html
Floats - http://investorshub.advfn.com/boards/board.aspx?board_id=15223
Fool.com - http://www.fool.com
Forbes - http://www.forbes.com/home_usa
Form 4 Filings - http://www.secform4.com/index.php
Google News Business - http://news.google.com/?ned=us&topic=b
Google News Home - http://news.google.com/
Holiday Schedule for Stock Markets - http://www.allstocks.com/html/stock_markets_holidays.html
High Short Interest Stocks - http://www.highshortinterest.com/
Insider Buy & Sell Info - http://www.insidercow.com/latestFillings/buyByCompany.jsp;jsessionid=00CD11F05D6090BBECE249167FD45A5B
Investing Glossary - http://www.investorwords.com/
Investopedia - http://www.investopedia.com/?viewed=1
Investors Business Daily - http://www.investors.com
Investor Words - http://www.investorwords.com/
Knobias - http://www.knobias.com/individual/public/quote.htm
Level 2 Video Tutorial - http://stockhideout.com/images/flash/level.html
Low Float Stocks - http://www.lowfloat.com/
MarketWatch.com - http://www.marketwatch.com/
Message, Blog & Twitter Postings - http://www.thelion.com
MicrocapMarkets NASDAQ <$5 - http://www.microcapmarkets.com/data_main_nav.jsp?market=NASDAQ
MicrocapMarkets OTCBB - http://www.microcapmarkets.com/data_main_nav.jsp?market=OTCBB
Mining - http://www.miningmx.com/
MSN Money Central - http://www.moneycentral.msn.com/investor/home.asp
Multicollinearity - www.stockcharts.com/help/doku.php
Mutual Fund Facts About Individual Stocks - http://www.mffais.com/
Naked Shorting - www.businessjive.com/
NASDAQ Stock Market - http://www.nasdaq.com/
NASDAQ/NYSE/AMEX Stock Info - www.secfilings.com/
Natural Resources News & Commentary - http://www.resourceinvestor.com/Pages/default.aspx
New York Stock Exchange - http://www.nyse.com/home.html
OTCBB Daily List - http://www.otcbb.com/dailylist/
Patterns - http://thepatternsite.com/
Pinksheets Stock Info - www.otcmarkets.com/pink/index.jsp
Platform - http://www.quotetracker.com/
Precious Metals - http://www.kitco.com/
Press Releases - http://www.prnewswire.com/news-releases/
REG SHO List - www.regsho.com/tools/short_list.php
Regional Bank List - http://www.bullsector.com/regionalbanks.html
Reverse Phone & Address - http://www.whitepages.com/reverse-lookup
Reverse Mergers - http://www.gopublic.com/reversemerger.html
Reverse Merger Report - http://reversemerger.dealflowmedia.com
Reverse Splits - http://investorshub.advfn.com/boards/board.aspx?board_id=3017
Screener - http://clearstation.com
Screener - http://smallcapcenter.com
Searching Blogs, News, etc. - http://www.icerocket.com/
SEC - http://www.sec.gov
SEC Filings - http://www.edgar-online.com/
SEC Filings - http://www.sec.gov/edgar/searchedgar/companysearch.html
SEC Filings - http://www.secinfo.com
SEC Form Types and Definitions - http://learn.westlawbusiness.com/support/formtypes.html
Secretary of State Sites - All states: http://www.coordinatedlegal.com/SecretaryOfState.html
Seeking Alpha BioTech Stocks - http://www.seekingalpha.com/sector/biotech
Shell Stocks - http://www.shellstockreview.com
SHO Threshold List - http://www.nasdaqtrader.com/Trader.aspx?id=RegSHOThreshold
Short Stocks - http://shortsqueeze.com/
Stock Chart Patterns - www.trending123.com/patterns/index.html
Stock Promotions - www.stockpromoters.com
Stock Promotions - www.stockreads.com/
Stock Research - http://www.stockhouse.com
Stock Scanning - http://bigcharts.marketwatch.com/markets/screener.asp?exchange=118&screen=1&x=15&y=18
Stock Scanning - http://clearstation.etrade.com/cgi-bin/events?Cmd=techev
Stock Scanning - http://markets.usatoday.com/custom/usatoday-com/screener/screener.asp
Stock Scanning - http://screen.yahoo.com/stocks.html
Stock Scanning - http://stockcharts.com/def/servlet/SC.scan
Stock Scanning - http://www.acmechart.com/
Stock Scanning - http://www.americanbulls.com/
Stock Scanning - http://www.barchart.com/
Stock Scanning - http://www.prophet.net/scans/index.jsp
Stock Scanning - http://www.smallcapcenter.com/tools_technicalSearch.asp?page=ANALYTICSSEARCH_IN.ASP
Stock Scanning - http://www.stockciphering.com/index.htm
Stock Scanning - http://www.stockfetcher.com/
Stock Scanning - http://www.stockscores.com/index.asp
Stock Scanning - http://www.stockworm.com/help/tours/stock-screener.html;jsessionid=aEg_MdzO2SH9
Stock Scanning - http://www2.barchart.com/
Technical Analysis - http://stockta.com/
Technical Indicators/Overlays - www.stockcharts.com/school/doku.php
TheStreet.Com - http://www.thestreet.com/
Trading Halts - http://www.nasdaqtrader.com/Trader.aspx?id=TradeHalts
Trading Platform - www.equityfeed.com
Trading Stations - http://www.tradingcomputers.com/index.html
Transfer Agent Contact Information - http://investorshub.advfn.com/boards/board.aspx?board_id=10067
Transfer Agents in the United States - http://www.stocktransfer.com/index.cfm?action=about.network.transferAgents
Translation Tool - http://www.verbatimsolutions.com/freetranslation.php
USAToday Business - http://markets.usatoday.com/custom/usatoday-com/html-markets.asp
http://ir.stg.com/phoenix.zhtml?c=254164&p=irol-sec
m1999
Posts Today
|
0
|
Posts (Total)
|
12198
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |